Arvinas, Inc. (NASDAQ:ARVN) CFO Sells $51,529.85 in Stock

Arvinas, Inc. (NASDAQ:ARVN – Get Rating) CFO Sean A. Cassidy sold 1,745 shares of Arvinas stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $29.53, for a total value of $51,529.85. Following the sale, the chief financial officer now owns 183,618 shares in the company, valued at $5,422,239.54. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Arvinas Price Performance

ARVN stock opened at $31.39 on Monday. Arvinas, Inc. has a 12 month low of $27.00 and a 12 month high of $75.39. The firm has a market cap of $1.67 billion, a PE ratio of -5.90 and a beta of 1.78. The firm has a 50 day simple moving average of $33.19 and a 200 day simple moving average of $39.89.

Arvinas (NASDAQ:ARVN – Get Rating) last released its earnings results on Thursday, February 23rd. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.46). Arvinas had a negative return on equity of 43.79% and a negative net margin of 228.19%. The company had revenue of $38.00 million during the quarter, compared to analysts’ expectations of $35.32 million. During the same quarter in the previous year, the company earned ($1.00) EPS. The firm’s quarterly revenue was up 32.4% compared to the same quarter last year. As a group, sell-side analysts expect that Arvinas, Inc. will post -6.01 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ARVN. Cantor Fitzgerald restated an “overweight” rating and set a $90.00 target price on shares of Arvinas in a report on Tuesday, January 31st. Morgan Stanley decreased their price objective on Arvinas from $57.00 to $36.00 and set an “equal weight” rating on the stock in a research note on Monday, February 27th. Barclays cut their price target on Arvinas from $90.00 to $70.00 and set an “overweight” rating for the company in a report on Wednesday, November 23rd. Guggenheim cut Arvinas from a “buy” rating to a “neutral” rating in a report on Thursday, January 12th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $81.00 price target on shares of Arvinas in a research note on Monday, November 28th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.44.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. New England Capital Financial Advisors LLC bought a new position in shares of Arvinas during the 4th quarter worth about $34,000. Royal Bank of Canada grew its holdings in Arvinas by 37.6% during the third quarter. Royal Bank of Canada now owns 1,230 shares of the company’s stock valued at $54,000 after purchasing an additional 336 shares during the period. Natixis bought a new position in Arvinas in the fourth quarter valued at approximately $54,000. Lazard Asset Management LLC bought a new position in Arvinas in the first quarter valued at approximately $57,000. Finally, SeaCrest Wealth Management LLC bought a new stake in shares of Arvinas in the second quarter worth $57,000. 92.03% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Company Profile

(Get Rating)

Arvinas, Inc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.